Angel M. Segura-Huerta - Publications

Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

Journal: Neuroendocrinology

Published: January 21, 2026

Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 01, 2025

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

Journal: Nature communications

Published: October 17, 2022

Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.

Journal: European thyroid journal

Published: June 13, 2022

Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Journal: Cancers

Published: December 10, 2021

Distance decay 2.0 - A global synthesis of taxonomic and functional turnover in ecological communities.

Journal: Global ecology and biogeography : a journal of macroecology

Published: August 23, 2021

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families.

Journal: Journal of personalized medicine

Published: April 26, 2021

Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.

Journal: Cancer communications (London, England)

Published: December 25, 2020

External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.

Journal: Neuroendocrinology

Published: October 30, 2020

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).

Journal: Health and quality of life outcomes

Published: June 30, 2020

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 08, 2019

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.

Journal: Oncotarget

Published: September 13, 2018